| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | A full length recombinant human protein was used as the immunogen for the CDC34 antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
Cell cycle events are regulated by the sequential activation and deactivation of cyclin dependent kinases (Cdks) and by the proteolysis of cyclins. The cell division cycle (Cdc) genes are required at various points in the cell cycle. Cdc25A, Cdc25B and Cdc25C protein tyrosine phosphatases function as mitotic activators by dephosphorylating Cdc2 p34 on regulatory tyrosine residues. Cdc6 is the human homolog of Saccharomyces cerevisiae Cdc6, which is involved in the initiation of DNA replication. Cdc37 appears to facilitate Cdk4/cyclin D1 complex formation and has been shown to form a stable complex with HSP 90. Cdc34, Cdc27 and Cdc16 function as ubiquitinconjugating enzymes. Cdc34 is thought to be the structural and functional homolog of Saccharomyces cerevisiae Cdc34, which is essential for the G1 to S phase transition. Cdc16 and Cdc27 are components of the APC (anaphasepromoting complex) which ubiquitinates cyclin B, resulting in cyclin B/Cdk complex degradation.
This anti-CDC34 antibody is supplied as Purified (Mouse, Monoclonal (mouse origin), clone CPTC-CDC34-2, Mouse IgG1, kappa, Unconjugated) and is designed to support common target-detection workflows after the on-page specifications.
Key elements and design rationale
- Target: CDC34
- Format: Purified
- Localization: Cytoplasmic, nuclear
- Species reactivity: Human
- Applications (listed): IHC-P, WB
- Conjugate: Unconjugated
- Clone and antibody class: Monoclonal (mouse origin), clone CPTC-CDC34-2, Mouse IgG1, kappa
Because antibody performance can depend on epitope context, sample preparation, and biological state, interpret signals using appropriate controls and orthogonal evidence when possible.
Biological background
CDC34 is referenced in public gene/protein resources (e.g., UniProt and NCBI Gene), which provide curated names/synonyms, protein features, and pathway context. When designing assays, consider potential isoforms, post-translational modifications, and cell-type specific expression that may influence observed signal.
Research relevance and current trends
- Profiling CDC34 expression across model systems, perturbations, and time points to support mechanistic hypotheses.
- Combining antibody-based detection with multi-omics or imaging readouts to link CDC34 signal with phenotype.
- Using well-matched controls (isotype controls, genetic perturbations, or independent reagents) to strengthen interpretation of target-associated signal.
Common research applications
- IHC-P
- WB
Use the listed applications as a starting point and tailor experimental design to your sample type and readout requirements.
Notes for experimental interpretation
- Specificity considerations: closely related family members, isoforms, or PTMs can affect apparent specificity; confirm with independent approaches when critical.
- Controls: include negative controls and, when feasible, genetic or pharmacologic perturbations to support target attribution in your system.
- Species and sample context: differences in sequence, expression, fixation, or extraction conditions can change signal behavior across models.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.